Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FTD-TPI + bevacizumab-UMC Utrecht
- Development stage
- Unknown
- Lead developer
- University Medical Center Utrecht
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous, Intra-arterial
01
Overview
FTD-TPI + bevacizumab-UMC Utrecht refers to a combination therapy regimen being evaluated in the Phase II STARLIGHT trial at University Medical Center Utrecht. This therapeutic approach combines systemic treatment with trifluridine/tipiracil (FTD-TPI, an oral nucleoside-based chemotherapy) and bevacizumab (a monoclonal antibody targeting VEGF) alongside localized, individualized radioembolization using holmium-166 (166Ho) microspheres. The regimen is specifically investigated for patients with refractory, liver-dominant metastatic colorectal cancer (mCRC). FTD-TPI serves as both a cytotoxic agent and a potential radiosensitizer, while bevacizumab inhibits tumor angiogenesis and 166Ho-microspheres deliver targeted internal beta-radiation to hepatic lesions. The goal of this multi-modal strategy is to improve disease control in both intrahepatic and extrahepatic sites for patients who have failed standard therapies including fluoropyrimidines, oxaliplatin, and irinotecan.
- Brand names
- LonsurfAvastinQuiremSpheres
- Other names
- trifluridine/tipiracil + bevacizumab + 166Ho-microspheresTAS-102 + bevacizumab + holmium-166 radioembolization
02
Targets
Beyond the preview
Go deeper on FTD-TPI + bevacizumab-UMC Utrecht.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FTD-TPI + bevacizumab-UMC Utrecht.